» Articles » PMID: 37304007

Comprehensive Analysis of the Expression and Prognosis for APOE in Malignancies: A Pan-cancer Analysis

Overview
Journal Oncol Res
Specialty Oncology
Date 2023 Jun 12
PMID 37304007
Authors
Affiliations
Soon will be listed here.
Abstract

Apolipoprotein E (), a gene identified as one of the strongest genetic factors contributing to the risk determinant of developing late-onset Alzheimer's disease (AD), may also contribute to the risk of cancer. However, no pan-cancer analysis has been conducted specifically for the gene. In this study, we investigated the oncogenic role of the gene across cancers by GEO (Gene Expression Omnibus) and TCGA (The Cancer Genome Atlas). Based on the available data, we found that most cancer types overexpress , and clear associations exist between the expression level of and prognosis in tumor patients. The expression of also correlates with certain gender-associated tumors including, ovarian cancer, uterine carcinosarcoma, and breast cancer. However, there is a significant negative association between cancer-associated fibroblast infiltration levels and the expression level of in testicular germ cell tumors. Moreover, acute inflammatory response and protein-activation cascade-associated functions play an important role in the functional mechanisms of APOE. The present pan-cancer analysis of APOE shows that the protein phosphorylation, DNA methylation, and genetic alterations of APOE have a significant clinical relevance for survival prognosis and immune cell infiltration. This novel pan-cancer study outlines the current understanding of APOE oncogenic roles across thirty-three cancers and highlights the complex association between AD and cancers.

Citing Articles

Human apolipoprotein E glycosylation and sialylation: from structure to function.

Moon H, Luo Y, Chugh D, Zhao L Front Mol Neurosci. 2024; 17:1399965.

PMID: 39169951 PMC: 11335735. DOI: 10.3389/fnmol.2024.1399965.


Recent Advancements in Research on DNA Methylation and Testicular Germ Cell Tumors: Unveiling the Intricate Relationship.

Nicu A, Ionel I, Stoica I, Burlibasa L, Jinga V Biomedicines. 2024; 12(5).

PMID: 38791003 PMC: 11117643. DOI: 10.3390/biomedicines12051041.

References
1.
Mishra S, Blazey T, Holtzman D, Cruchaga C, Su Y, Morris J . Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype. Brain. 2018; 141(6):1828-1839. PMC: 5972633. DOI: 10.1093/brain/awy103. View

2.
Musicco M, Adorni F, Di Santo S, Prinelli F, Pettenati C, Caltagirone C . Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study. Neurology. 2013; 81(4):322-8. DOI: 10.1212/WNL.0b013e31829c5ec1. View

3.
Chiba T, Kondo Y, Shinozaki S, Kaneko E, Ishigami A, Maruyama N . A selective NFkappaB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice. J Atheroscler Thromb. 2006; 13(6):308-13. DOI: 10.5551/jat.13.308. View

4.
Asaro A, Carlo-Spiewok A, Malik A, Rothe M, Schipke C, Peters O . Apolipoprotein E4 disrupts the neuroprotective action of sortilin in neuronal lipid metabolism and endocannabinoid signaling. Alzheimers Dement. 2020; 16(9):1248-1258. DOI: 10.1002/alz.12121. View

5.
Tang Z, Kang B, Li C, Chen T, Zhang Z . GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019; 47(W1):W556-W560. PMC: 6602440. DOI: 10.1093/nar/gkz430. View